×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRUS – merus n.v. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRUS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/16
04:01 pm
mrus
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
Medium
Report
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
12/10
12:27 pm
mrus
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy [Yahoo! Finance]
Neutral
Report
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy [Yahoo! Finance]
12/10
08:01 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Citigroup Inc. from $89.00 to $97.00. They now have a "buy" rating on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Citigroup Inc. from $89.00 to $97.00. They now have a "buy" rating on the stock.
12/9
08:11 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
12/7
01:34 am
mrus
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC [Yahoo! Finance]
Medium
Report
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC [Yahoo! Finance]
12/7
01:30 am
mrus
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Medium
Report
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
12/6
03:24 pm
mrus
FDA Roundup: December 6, 2024 [Yahoo! Finance]
Low
Report
FDA Roundup: December 6, 2024 [Yahoo! Finance]
12/4
04:58 pm
mrus
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study [Yahoo! Finance]
Medium
Report
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
09:52 pm
mrus
Form SCHEDULE 13G Merus N.V. Filed by: COMMODORE CAPITAL LP
Medium
Report
Form SCHEDULE 13G Merus N.V. Filed by: COMMODORE CAPITAL LP
12/5
06:04 am
mrus
Form 8-K Merus N.V. For: Dec 04
Medium
Report
Form 8-K Merus N.V. For: Dec 04
12/2
08:43 am
mrus
Form 8-K Merus N.V. For: Nov 27
Medium
Report
Form 8-K Merus N.V. For: Nov 27
11/14
04:07 pm
mrus
Form SC 13G/A Merus N.V. Filed by: COMMODORE CAPITAL LP
Medium
Report
Form SC 13G/A Merus N.V. Filed by: COMMODORE CAPITAL LP
11/14
01:34 pm
mrus
Form SC 13G/A Merus N.V. Filed by: SAMLYN CAPITAL, LLC
Low
Report
Form SC 13G/A Merus N.V. Filed by: SAMLYN CAPITAL, LLC
11/14
08:55 am
mrus
Form SC 13G/A Merus N.V. Filed by: Flynn James E
Low
Report
Form SC 13G/A Merus N.V. Filed by: Flynn James E
11/14
06:28 am
mrus
Form SC 13G Merus N.V. Filed by: RTW INVESTMENTS, LP
Low
Report
Form SC 13G Merus N.V. Filed by: RTW INVESTMENTS, LP
11/12
10:33 am
mrus
Form SC 13G Merus N.V. Filed by: FMR LLC
Low
Report
Form SC 13G Merus N.V. Filed by: FMR LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update
34.7%
10/25 Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 16.3%
1/15 Form 4 Merus N.V. For: Jan 13 Filed by: BVF INC/IL 13.8%
9/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.8%
4/3 Form 4 Merus N.V. For: Apr 01 Filed by: Throsby Mark 9.8%
11/4 Form 6-K Merus N.V. For: Nov 04 7.0%
4/24 Form SC 13G/A Merus N.V. Filed by: EcoR1 Capital, LLC 6.8%
3/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.3%
8/10 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
4/16 Form 8-K Merus N.V. For: Apr 15 5.8%
10/25 Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 16.3%
1/15 Form 4 Merus N.V. For: Jan 13 Filed by: BVF INC/IL 13.8%
9/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.8%
4/3 Form 4 Merus N.V. For: Apr 01 Filed by: Throsby Mark 9.8%
11/4 Form 6-K Merus N.V. For: Nov 04 7.0%
4/24 Form SC 13G/A Merus N.V. Filed by: EcoR1 Capital, LLC 6.8%
3/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.3%
8/10 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
4/16 Form 8-K Merus N.V. For: Apr 15 5.8%
TOP News Decliners
10/27
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
-16.2%
3/18 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -10.8%
3/10 Form 4 Merus N.V. For: Mar 04 Filed by: Throsby Mark -8.1%
4/29 Form 10-K/A Merus N.V. For: Dec 31 -7.5%
8/19 Form 6-K Merus N.V. For: Jun 30 -6.9%
4/30 Form POS AM Merus N.V. -6.6%
3/7 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -6.2%
5/20 Merus to Present at the RBC Capital Markets 2019 Healthcare Conference -5.9%
10/23 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
4/6 Form 4 Merus N.V. For: Apr 02 Filed by: Throsby Mark -4.6%
3/18 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -10.8%
3/10 Form 4 Merus N.V. For: Mar 04 Filed by: Throsby Mark -8.1%
4/29 Form 10-K/A Merus N.V. For: Dec 31 -7.5%
8/19 Form 6-K Merus N.V. For: Jun 30 -6.9%
4/30 Form POS AM Merus N.V. -6.6%
3/7 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -6.2%
5/20 Merus to Present at the RBC Capital Markets 2019 Healthcare Conference -5.9%
10/23 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
4/6 Form 4 Merus N.V. For: Apr 02 Filed by: Throsby Mark -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: